Vaccine Adverse Reaction Clinical Trial
Official title:
Gender-dependent Symptoms Following Anti-COVID-19 Vaccine in a Lebanese and Italian Populations
In 2021 and following the COVID-19 (corona virus disease 2019) pandemic, different vaccines were initially authorized in Italy and Lebanon. Notably, vaccine side effects were poorly recorded. Thus, the investigator performed a survey study to monitor COVID-19 vaccine side effects among Italian and Lebanese citizens according to gender and age through a web-based questionnaire in Italian and Arabic languages including 21 items by "Google Form", investigating 13 symptoms, and employing social-media platforms
The COVID-19 pandemic has presented a real challenge to the public health system worldwide since the year 2019, spreading to more than 200 countries and regions worldwide.The emergence and rapid spread of COVID-19 were caused by the coronavirus SARS-CoV-2. Worldwide, the use of COVID-19 vaccines was initially authorized for emergency use and the side effects were not stated clearly. Common side effects were expected but specific side effects linked with COVID-19 vaccines remained uncertain. In this context, survey studies are needed for a comprehensive evaluation of the relationships between vaccine administration, related undesired effects and vaccine safety. This study represents the first survey following early COVID-19 vaccines administration in two geographic areas, comparatively considering possible differences due to gender and age. A web-based survey was conducted on a cohort of 1975 Italian and 822 Lebanese people who received at least one dose of COVID-19 vaccine. The study was conducted between March and July 2021 on a voluntary basis, and by a tailored anonymous web-based questionnaire. The protocol was approved by the local Ethics Committee, University of Bari 'Aldo Moro' (study number 6752, protocol number 0031044). A specific questionnaire was designed in English and translated into Italian and Arabic. It contains 21 items including demographic data, the history of vaccine administration before COVID-19, the administration of the first and second dose of COVID-19 vaccine, and possible adverse effects. The survey link was shared by a "Google Form" employing social-media platforms or by personal interview. The questionnaire explored the presence of 13 possible symptoms appearing following the administration of the first and second dose of COVID-19 vaccine: pain at the injection site, redness at the injection site, swelling at the injection site, induration at the injection site, allergic-urticarial reaction, anaphylaxis, fever (>37 °C), diarrhea, vomiting, asthenia/fatigue, muscle pain, rash, sleepiness/insomnia, irritability/nervousness, headache, lymphadenopathy. The presence and intensity of symptoms were assessed semi-quantitatively by a Visual Analogue Scale (VAS). Besides symptoms, the following aspects were also evaluated: need of drug intake, consultation of a doctor, emergency admission to hospital, and possible hospitalization. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03966391 -
Effectiveness of CARD for Improving School-Based Immunizations
|
N/A | |
Completed |
NCT04530357 -
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
|
Phase 1/Phase 2 | |
Terminated |
NCT03966300 -
Improving the School Vaccination Experience: What CARDs Are You Going to Play?
|
N/A | |
Active, not recruiting |
NCT06286488 -
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
|
Phase 4 | |
Recruiting |
NCT05546502 -
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
|
Phase 3 | |
Active, not recruiting |
NCT05483725 -
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
|
||
Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05128721 -
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
|
Phase 1 | |
Withdrawn |
NCT04894682 -
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
|
||
Not yet recruiting |
NCT05387252 -
Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines
|
N/A | |
Active, not recruiting |
NCT04801667 -
Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT05283902 -
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
|
||
Recruiting |
NCT05095844 -
National Vaccine Adverse Event Reporting Survey and Etiology
|
||
Recruiting |
NCT05315856 -
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
|
||
Recruiting |
NCT05898464 -
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
|
Phase 4 | |
Recruiting |
NCT05212792 -
Genomics and COVID-19 Vaccine Adverse Events
|
||
Recruiting |
NCT05258708 -
COVID-19 Vaccine Reactogenicity and Immunogenicity
|